Maze Therapeutics (NASDAQ:MAZE) SVP Amy Bachrodt Sells 2,500 Shares

Maze Therapeutics, Inc. (NASDAQ:MAZE) SVP Amy Bachrodt sold 2,500 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $29.44, for a total transaction of $73,600.00. Following the transaction, the senior vice president directly owned 12,965 shares of the company’s stock, valued at $381,689.60. The trade was a 16.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Amy Bachrodt also recently made the following trade(s):

• On Monday, February 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $46.04, for a total transaction of $230,200.00.
• On Thursday, January 22nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The shares were sold at an average price of $45.52, for a total value of $227,600.00.
• On Friday, January 2nd, Amy Bachrodt sold 5,000 shares of Maze Therapeutics stock. The stock was sold at an average price of $39.15, for a total value of $195,750.00.

Maze Therapeutics Price Performance

Shares of MAZE stock opened at $28.71 on Friday. Maze Therapeutics, Inc. has a 12-month low of $6.71 and a 12-month high of $53.65. The firm has a market capitalization of $1.43 billion, a price-to-earnings ratio of -8.89 and a beta of 5.16. The business has a 50 day simple moving average of $44.44 and a 200 day simple moving average of $37.87.

Maze Therapeutics (NASDAQ:MAZE) last announced its earnings results on Wednesday, March 25th. The company reported ($0.65) earnings per share for the quarter, beating the consensus estimate of ($0.73) by $0.08.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the stock. Guggenheim upped their price objective on shares of Maze Therapeutics from $46.00 to $58.00 and gave the stock a “buy” rating in a report on Wednesday, March 4th. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Thursday, January 22nd. Lifesci Capital raised shares of Maze Therapeutics to a “strong-buy” rating in a research note on Thursday, December 18th. Wells Fargo & Company initiated coverage on shares of Maze Therapeutics in a report on Thursday, December 4th. They issued an “overweight” rating and a $55.00 price objective for the company. Finally, Wedbush raised their price objective on shares of Maze Therapeutics from $43.00 to $58.00 and gave the company an “outperform” rating in a research note on Monday, March 16th. Three investment analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $66.44.

Institutional Trading of Maze Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in MAZE. Janus Henderson Group PLC grew its position in Maze Therapeutics by 318.0% in the fourth quarter. Janus Henderson Group PLC now owns 3,142,587 shares of the company’s stock worth $130,197,000 after buying an additional 2,390,713 shares during the last quarter. Vanguard Group Inc. lifted its position in shares of Maze Therapeutics by 218.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,334,955 shares of the company’s stock valued at $34,615,000 after acquiring an additional 915,342 shares during the last quarter. Marshall Wace LLP boosted its stake in shares of Maze Therapeutics by 3,868.5% during the 3rd quarter. Marshall Wace LLP now owns 777,701 shares of the company’s stock worth $20,166,000 after acquiring an additional 758,104 shares in the last quarter. Caligan Partners LP bought a new stake in shares of Maze Therapeutics during the 4th quarter worth $22,794,000. Finally, ArrowMark Colorado Holdings LLC acquired a new position in shares of Maze Therapeutics in the 3rd quarter worth $14,135,000.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.